{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:51:45Z","timestamp":1793713905510,"version":"4.6.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,1]]},"DOI":"10.2169\/internalmedicine.1326-22","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T22:11:05Z","timestamp":1678831865000},"page":"3251-3254","source":"Crossref","is-referenced-by-count":6,"title":["The Onset of IgG4-related Retroperitoneal Fibrosis under Administration of a TNF Inhibitor in a Rheumatoid Arthritis Patient"],"prefix":"10.2169","volume":"62","author":[{"given":"Takao","family":"Ogawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Nishinomiya Municipal Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shimagami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nishinomiya Municipal Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nishinomiya Municipal Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 36: 1773-1781, 2021.","DOI":"10.1093\/ndt\/gfaa083"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fenaroli P, Maritati F, Vaglio A. Into clinical practice: diagnosis and therapy of retroperitoneal fibrosis. Curr Rheumatol Rep 23: 18, 2021.","DOI":"10.1007\/s11926-020-00966-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liu Y, Zhu L, Wang Z, et al. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Rheumatology (Oxford) 60: 767-772, 2021.","DOI":"10.1093\/rheumatology\/keaa411"},{"key":"4","unstructured":"4. Catanoso MG, Spaggiari L, Magnani L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 30: 776-778, 2012."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jalaj S, Dunbar K, Campbell A, Kazim M. Treatment of pediatric IgG4-related orbital disease with TNF-\u03b1 inhibitor. Ophthal Plast Reconstr Surg 34: e10-e12, 2018.","DOI":"10.1097\/IOP.0000000000000959"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 64: 828-833, 2005.","DOI":"10.1136\/ard.2004.029793"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wallwork R, Wallace Z, Perugino C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore) 97: e12631, 2018.","DOI":"10.1097\/MD.0000000000012631"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Almeqdadi M, Al-Dulaimi M, Perepletchikov A, Tomera K, Jaber BL. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: a case report and literature review. Clin Nephrol Case Stud 6: 4-10, 2018.","DOI":"10.5414\/CNCS109321"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hamdan A, Moeen Z, Tariq H, et al. An interesting case of immunoglobulin G4-related retroperitoneal fibrosis treated with rituximab. Cureus 13: e17940, 2021.","DOI":"10.7759\/cureus.17940"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 4: 40, 2020.","DOI":"10.1186\/s41927-020-00140-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Brasselet D, Chouchana L, Vial T, Damin-Pernik M, Lebrun-Vignes B. Drug-induced retroperitoneal fibrosis: a case\/non-case study in the French PharmacoVigilance Database. Expert Opin Drug Saf 19: 903-914, 2020.","DOI":"10.1080\/14740338.2020.1766022"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2: e000239, 2016.","DOI":"10.1136\/rmdopen-2015-000239"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Minaga K, Watanabe T, Hara A, et al. Identification of serum IFN-\u03b1 and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. Sci Rep 10: 14879, 2020.","DOI":"10.1038\/s41598-020-71848-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Watanabe T, Minaga K, Kamata K, Kudo M, Strober W. Mechanistic insights into autoimmune pancreatitis and IgG4-related disease. Trends Immunol 39: 874-889, 2018.","DOI":"10.1016\/j.it.2018.09.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vultaggio A, Nencini F, Carraresi A, et al. IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution. Allergy 73: 2172-2181, 2018.","DOI":"10.1111\/all.13471"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1326-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T03:24:29Z","timestamp":1699068269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1326-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":15,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1326-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"article-number":"1326-22"}}